TOP TEN perturbations for 390_at (Homo sapiens)
Organism: Homo sapiens
Gene: 390_at
Selected probe(set): 208376_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 390_at (208376_at) across 6674 perturbations tested by GENEVESTIGATOR:
B-CLL study 11 (rolipram) / rolipram study 4 (normal T-cell; 20uM)
Relative Expression (log2-ratio):-3.727275Number of Samples:4 / 4
| Experimental | B-CLL study 11 (rolipram) |
| Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. PBMCs' samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l. ATC code:--- | |
| Control | rolipram study 4 (normal T-cell; 20uM) |
| MACS purified T-cells from healthy donor peripheral blood treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. ATC code:--- |
B-CLL study 11 (DMSO) / vehicle (DMSO) treated normal T-cell sample
Relative Expression (log2-ratio):-3.1346092Number of Samples:4 / 4
| Experimental | B-CLL study 11 (DMSO) |
| Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with vehicle (DMSO) for 4 hours. PBMCs' samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l. | |
| Control | vehicle (DMSO) treated normal T-cell sample |
| MACS purified T-cells from healthy donor peripheral blood treated with vehicle (DMSO) for 4 hours. |
ingenol mebutate study 1 (uninvolved skin; 2d; 0.05%) / uninvolved skin sample (baseline)
Relative Expression (log2-ratio):2.323865Number of Samples:6 / 5
| Experimental | ingenol mebutate study 1 (uninvolved skin; 2d; 0.05%) |
| Punch biopsies of uninvolved skin obtained from actinic keratosis patients after 2 days treatment with ingenol mebutate 0.05% gel. Samples were taken one day after the second topical application with ingenol mebutate from cca 25-cm2 area of uninvolved, normal-appearing, aged but non-sun-exposed skin on the inner aspect of the upper arm. The biopsies were formalin fixed and paraffin embedded. Patients were ≥ 18 years of age and had two to five clinically typical, visible, and discrete AK lesions within a contiguous 25 cm2 area on the upper extremity (dorsum of hands or forearm) and with one additional AK lesion located 1 to 5 cm from the AK treatment area. Further the donors had uninvolved skin area on the inner aspect of the upper arm. ATC code: | |
| Control | uninvolved skin sample (baseline) |
| Punch biopsies of uninvolved skin obtained from actinic keratosis (AK) patients before treatment (baseline). Samples were taken from cca 25 cm2 area of uninvolved, normal-appearing, aged but non-sun-exposed skin on the inner aspect of the upper arm. The biopsies were formalin fixed and paraffin embedded. Patients were ≥ 18 years of age and had two to five clinically typical, visible, and discrete AK lesions within a contiguous 25 cm2 area on the upper extremity (dorsum of hands or forearm) and with one additional AK lesion located 1 to 5 cm from the AK treatment area. Further the donors had uninvolved skin area on the inner aspect of the upper arm. |
actinic keratosis study 4 (lesion; ingenol mebutate; 2d; 0.05%) / actinic keratosis study 4 (lesion; baseline)
Relative Expression (log2-ratio):1.7596941Number of Samples:5 / 6
| Experimental | actinic keratosis study 4 (lesion; ingenol mebutate; 2d; 0.05%) |
| Punch biopsies of skin lesions obtained from actinic keratosis patients after 2 days treatment with ingenol mebutate 0.05% gel. Samples were taken one day after the second topical application with ingenol mebutate from cca 25 cm2 treated area. The biopsies were formalin fixed and paraffin embedded. Patients were ≥ 18 years of age and had 2-5 clinically typical, visible, and discrete AK lesions within a contiguous 25 cm2 area on the upper extremity (dorsum of hands or forearm) and with one additional AK lesion located 1 to 5 cm from the AK treatment area. Further the donors had uninvolved skin area on the inner aspect of the upper arm. ATC code: | |
| Control | actinic keratosis study 4 (lesion; baseline) |
| Punch biopsies of skin lesions obtained from actinic keratosis (AK) patients before treatment (baseline). The biopsies were formalin fixed and paraffin embedded. Patients were ≥ 18 years of age and had two to five clinically typical, visible, and discrete AK lesions within a contiguous 25 cm2 area on the upper extremity (dorsum of hands or forearm) and with one additional AK lesion located 1 to 5 cm from the AK treatment area. Further the donors had uninvolved skin area on the inner aspect of the upper arm. |
cutaneous T-cell lymphoma study 1 (plaque phase) / normal skin tissue
Relative Expression (log2-ratio):1.6791382Number of Samples:7 / 8
| Experimental | cutaneous T-cell lymphoma study 1 (plaque phase) |
| Lesional skin biopsies from patients with cutaneous T-cell lymphoma in the plaque phase. | |
| Control | normal skin tissue |
| Skin biopsies from healthy individuals. |
PMA; ionomycine study 2 / unstimulated CD4 memory T-cell sample
Relative Expression (log2-ratio):1.6538372Number of Samples:8 / 8
| Experimental | PMA; ionomycine study 2 |
| CD4+ memory T cells derived from peripheral blood of healthy subjects were stimulated for 3 hours with phorbol 12-myristate 13-acetate (PMA, 10 ng/ml) and ionomycin (1 µg/ml). ATC code:--- | |
| Control | unstimulated CD4 memory T-cell sample |
| Unstimulated CD4+ memory T cells derived from peripheral blood of healthy subjects. |
actinic keratosis study 4 (lesion; ingenol mebutate; 1d; 0.05%) / actinic keratosis study 4 (lesion; baseline)
Relative Expression (log2-ratio):1.645647Number of Samples:6 / 6
| Experimental | actinic keratosis study 4 (lesion; ingenol mebutate; 1d; 0.05%) |
| Punch biopsies of skin lesions obtained from actinic keratosis patients after 1 day treatment with ingenol mebutate 0.05% gel. Samples were taken one day after the first topical application with ingenol mebutate from cca 25 cm2 treated area. The biopsies were formalin fixed and paraffin embedded. Patients were ≥ 18 years of age and had 2-5 clinically typical, visible, and discrete AK lesions within a contiguous 25 cm2 area on the upper extremity (dorsum of hands or forearm) and with one additional AK lesion located 1 to 5 cm from the AK treatment area. Further the donors had uninvolved skin area on the inner aspect of the upper arm. ATC code: | |
| Control | actinic keratosis study 4 (lesion; baseline) |
| Punch biopsies of skin lesions obtained from actinic keratosis (AK) patients before treatment (baseline). The biopsies were formalin fixed and paraffin embedded. Patients were ≥ 18 years of age and had two to five clinically typical, visible, and discrete AK lesions within a contiguous 25 cm2 area on the upper extremity (dorsum of hands or forearm) and with one additional AK lesion located 1 to 5 cm from the AK treatment area. Further the donors had uninvolved skin area on the inner aspect of the upper arm. |
septic shock study 3 (D3; non-survivor) / normal blood sample
Relative Expression (log2-ratio):-1.4565296Number of Samples:9 / 22
| Experimental | septic shock study 3 (D3; non-survivor) |
| Blood samples from patients (non-survivors) collected at day 3 (D3) after the septic shock onset. According to day 28 survival status, patients were classified as non-survivors. Septic shock patients were identified according to the diagnostic criteria of the American College of Chest Physicians/Society of Critical Care Medicine (1992). The onset of septic shock was defined as the beginning of vasopressor therapy in combination with an identifiable site of infection, persisting hypotension - despite fluid resuscitation - and evidence of a systemic inflammatory response manifested by at least two of the following criteria: a) temperature >38ºC or <36ºC; b) heart rate >90 beats/min; c) respiratory rate >20 breaths/min; d) white blood cell count >12,000/mm3 or <4000/mm3. Excluded were subjects that were less than 18 years old and had aplasia or immunosuppressive disease (e.g. HIV infection). | |
| Control | normal blood sample |
| Blood samples from healthy subjects. |
septic shock study 3 (D2; non-survivor) / normal blood sample
Relative Expression (log2-ratio):-1.4508181Number of Samples:8 / 22
| Experimental | septic shock study 3 (D2; non-survivor) |
| Blood samples from patients (non-survivors) collected at day 2 (D2) after the septic shock onset. According to day 28 survival status, patients were classified as non-survivors. Septic shock patients were identified according to the diagnostic criteria of the American College of Chest Physicians/Society of Critical Care Medicine (1992). The onset of septic shock was defined as the beginning of vasopressor therapy in combination with an identifiable site of infection, persisting hypotension - despite fluid resuscitation - and evidence of a systemic inflammatory response manifested by at least two of the following criteria: a) temperature >38ºC or <36ºC; b) heart rate >90 beats/min; c) respiratory rate >20 breaths/min; d) white blood cell count >12,000/mm3 or <4000/mm3. Excluded were subjects that were less than 18 years old and had aplasia or immunosuppressive disease (e.g. HIV infection). | |
| Control | normal blood sample |
| Blood samples from healthy subjects. |
dexamethasone study 9 (24h) / EtOH treated CCRF-CEM-C7H2 cell sample
Relative Expression (log2-ratio):1.379426Number of Samples:3 / 3
| Experimental | dexamethasone study 9 (24h) |
| CCRF-CEM-C7H2 cells cultured in the presence of dexamethansone (10e-7M) for 24 hours. ATC code:, , , , , , , , , , | |
| Control | EtOH treated CCRF-CEM-C7H2 cell sample |
| CCRF-CEM-C7H2 cells treated for 24 hours with 0.1% ethanol (EtOH) as carrier control. |